We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect Of Secoisolariciresinol Diglucoside (Sdg) On Colon Cancer Associated With Diabetes Mellitus.
- Authors
Patel, Bhoomika M.
- Abstract
Background and objectives: There is increased risk of colon cancer in both men and women having diabetes. The objective of the study was to evaluate the role of Secoisolariciresinol diglucoside (SDG) in colon cancer associated with type 2 diabetes mellitus. Methods: Diabetes was induced by administering high fat diet with low dose streptozotocin model. After 6 weeks, diabetes was confirmed and 1, 2 dimethylhydrazine(25mg/kg, sc) weekly administration was from 6th to 18th weeks. Rats were treated with the SDG(1mg/kg) orally from 6th to 24th week. After 24 weeks, various biochemical and enzymatic parameters were estimated. Animals were sacrificed and colon tissue was separated and subjected to analysis of histopathological, PCNA studies and mRNA expression of CDK4. For in vitro studies, MTT assay, scratch assay and clonogenic assay was carried out. Results: Disease control rats depicted hyperglycaemia, hyperinsulinaemia, elevated pro-inflammatory cytokines and cancer biomarker levels, and marked presence of proliferating cells. Treatment with SDG controlled hyperglycaemia, hyperinsulinaemia, reduced proinflammatory cytokines and cancer biomarker levels, and decreased no. of proliferating cells. We found that disease control rats depicted over expression of CDK4 mRNA levels which were reduced by SDG treatment. In vitro studies revealed that SDG showed a decrease in cell viability in MTT assay in HCT-15 cell line. IC 50 of simvastatin was calculated to be 21.25 uM. Similarly there was dose dependent decrease in clone formation as evaluated by clonogenic assay. There was decrease in the rate of migration with increase in concentration of SDG in scratch assay. Conclusions: Our data suggests that SDG exhibits protective role in colon cancer associated with diabetes mellitus as evident from control in glycemic parameters, reduction in tumor burden, tumor volume, tumor incidence and improvement in histopathological studies. The in vitro studies suggest that simvastatin acts possibly via inhibition of angiogenesis and down regulation of CDK4.
- Publication
Journal of Cancer Research & Therapeutics, 2017, Vol 13, pS433
- ISSN
0973-1482
- Publication type
Academic Journal